Investigation of the Cylex® ImmuKnow® Assay
Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Investigation of the Cylex® ImmuKnow® Assay|
None to be retained.
|Study Start Date:||November 2007|
|Study Completion Date:||December 2012|
|Primary Completion Date:||February 2010 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00569842
|United States, Indiana|
|Indiana Universtiy Simon Cancer Center|
|Indianapolis, Indiana, United States, 46202|
|Principal Investigator:||Sherif Farag, MD, PhD||Indiana University Simon Cancer Center|